帕罗西汀联合氟哌噻吨美利曲辛治疗脑卒中后重性抑郁障碍的临床观察
发布时间：2018-10-25 14:20
【摘要】：目的探讨帕罗西汀联合氟哌噻吨美利曲辛治疗脑卒中后重性抑郁障碍的临床应用价值。方法选取2015年2月至2017年10月期间我院收治的96例脑卒中后重性抑郁障碍患者作为研究对象,利用随机数字表法将其分为研究组、对照组,每组48例。对照组脑卒中后重性抑郁障碍患者在常规治疗基础上加用氟哌噻吨美利曲辛,20 mg/次,每日2次,连续服用28 d;研究组脑卒中后重性抑郁障碍患者在常规治疗基础上加用帕罗西汀,25 mg/次,1次/d,连续给药28 d,氟哌噻吨美利曲辛给药同对照组。结果两组脑卒中后重性抑郁障碍患者治疗完成率均为100.00%。两组脑卒中后重性抑郁障碍患者治疗前HAMD、NIHSS、SF-36、SCL-90量表评分对比无显著差异(P0.05),治疗后研究组HAMD、SCL-90、NIHSS量表评分较之前下降幅度以及SF-36量表评分上升幅度均优于对照组(P均0.05);两组各项药物相关不良反应发生率对比差异均无统计学意义,P均0.05。结论应用帕罗西汀、氟哌噻吨美利曲辛联合治疗脑卒中后重性抑郁障碍具有较为理想的应用效果,有利于保障患者生活质量、身心健康。
[Abstract]:Objective to investigate the clinical value of paroxetine combined with droperazone metriaxine in the treatment of post-stroke depressive disorder. Methods from February 2015 to October 2017, 96 patients with post-stroke depressive disorder were selected and divided into study group (n = 48) and control group (n = 48). In the control group, patients with severe depressive disorder after stroke were treated with droperazidone metriaxine for 20 mg/, twice a day, on the basis of routine treatment. The patients in the study group were treated with paroxetine, 25 mg/, once a day for 28 days. Results the complete rate of treatment in patients with severe depression after stroke was 100.00g. There was no significant difference in the scores of HAMD,NIHSS,SF-36,SCL-90 scale between the two groups before treatment (P0.05), but the decrease of HAMD,SCL-90,NIHSS scale and the increase of SF-36 scale in the study group were better than those in the control group (P0.05). There was no significant difference in the incidence of various drug related adverse reactions (P < 0.05). Conclusion the application of paroxetine and droperazone metriaxine in the treatment of post-stroke depressive disorder has an ideal effect, which is beneficial to the protection of patients' quality of life and physical and mental health.
【作者单位】： 沈阳医学院附属中心医院神经内四科;沈阳医学院附属中心医院检验科;
【分类号】：R743.3;R749.4
本文编号：2293945
[Abstract]:Objective to investigate the clinical value of paroxetine combined with droperazone metriaxine in the treatment of post-stroke depressive disorder. Methods from February 2015 to October 2017, 96 patients with post-stroke depressive disorder were selected and divided into study group (n = 48) and control group (n = 48). In the control group, patients with severe depressive disorder after stroke were treated with droperazidone metriaxine for 20 mg/, twice a day, on the basis of routine treatment. The patients in the study group were treated with paroxetine, 25 mg/, once a day for 28 days. Results the complete rate of treatment in patients with severe depression after stroke was 100.00g. There was no significant difference in the scores of HAMD,NIHSS,SF-36,SCL-90 scale between the two groups before treatment (P0.05), but the decrease of HAMD,SCL-90,NIHSS scale and the increase of SF-36 scale in the study group were better than those in the control group (P0.05). There was no significant difference in the incidence of various drug related adverse reactions (P < 0.05). Conclusion the application of paroxetine and droperazone metriaxine in the treatment of post-stroke depressive disorder has an ideal effect, which is beneficial to the protection of patients' quality of life and physical and mental health.
【作者单位】： 沈阳医学院附属中心医院神经内四科;沈阳医学院附属中心医院检验科;
【分类号】：R743.3;R749.4
【相似文献】
相关硕士学位论文 前4条
1 张天丽;脑卒中患者及其照顾者需求现状调查分析[D];天津医科大学;2017年
2 关琳;齐齐哈尔市某三甲医院不同亚型脑卒中患者的危险因素对比分析[D];吉林大学;2017年
3 蔡进华;吕梁市40岁以上居民脑卒中患病趋势及风险预测研究[D];山西医科大学;2017年
4 高华;非瓣膜性房颤相关性脑卒中的预后危险因素分析[D];第四军医大学;2017年
，本文编号：2293945
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2293945.html
最近更新
教材专著
